Previous 10 | Next 10 |
home / stock / xomap / xomap news
EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug App...
EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 202...
2023-09-01 07:30:00 ET Summary XOMA Corporation helps fund drug research and clinical trials in exchange for payments. Developing a new drug is expensive and high-risk, with a 90% failure rate in clinical trials. Along with its no-dividend Common, XOMA offers two preferred stocks ...
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Applicati...
2023-06-26 03:13:41 ET The biotech royalty aggregator, XOMA ( NASDAQ: XOMA ) has been added to the Russell 2000 and Russell 3000 Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. XOMA is a...
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000 ® and Russell 3000 ® Indexes following its annual reconstitution, which took effect after the U.S. markets close...
EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumi...
First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 fin...
2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Org...
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million c...
News, Short Squeeze, Breakout and More Instantly...
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Company Name:
XOMAP Stock Symbol:
NASDAQ Market:
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Website:
2024-07-02 09:00:25 ET XOMA Corp (XOMAP) declaring a stock dividend of $0.53906 per share on Ex-Date : July 03, 2024. Shareholders on record as of July 03, 2024 are eligible for the dividend. The payment date is scheduled for July 15, 2024, and the declaration was officially made on...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-05-26 12:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...